Physician profile
Stephen B Wiles
NPI 1932136959
$12,570.48
in general payments reported to CMS, 2019-2025
36 companies · $2,349 in 2025
The $2,349 reported for 2025 was more than what 90% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,039 · 2020: $896 · 2021: $2,404 · 2022: $1,599 · 2023: $2,752 · 2024: $1,532 · 2025: $2,349.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,327 · Travel and Lodging: $1,205 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,327.36 |
| Travel and Lodging | $1,204.97 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $2,483.41 | 2022-2025 | Envista Mx60 Iol, Ic-8 Apthera Iol, Stellaris Elite |
| Allergan, INC. | $2,447.11 | 2019-2022 | |
| Abbvie INC. | $1,665.74 | 2022-2025 | Lumigan, Alphagan P, Xen Glaucoma Treatment System |
| Alcon Vision LLC | $704.71 | 2022-2025 | Clareon, Rocklatan, Argos |
| Genentech USA, INC. | $617.66 | 2019-2025 | Vabysmo |
| Glaukos Corporation | $515.06 | 2019-2025 | Idosetr, Idose |
| Novartis Pharmaceuticals Corporation | $351.39 | 2019-2022 | |
| Aerie Pharmaceuticals, INC. | $347.29 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $331.61 | 2019-2023 | Cequa |
| Biogen, INC. | $292.87 | 2022-2024 | Byooviz |
| Harrow Eye, LLC | $285.52 | 2023-2025 | Iheezo |
| Tarsus Pharmaceuticals, INC. | $284.94 | 2024-2025 | Xdemvy |
| Mallinckrodt Hospital Products INC. | $239.14 | 2021-2025 | Acthar |
| Astellas Pharma US INC | $229.66 | 2023-2025 | Izervay |
| Dompe US, INC. | $211.61 | 2019-2025 | Oxervate |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $186.99 | 2019-2021 | |
| Kala Pharmaceuticals, INC. | $173.92 | 2019-2022 | |
| Apellis Pharmaceuticals, INC. | $159.01 | 2023-2025 | Syfovre |
| Sight Sciences, INC. | $150.55 | 2020-2025 | Omni Surgical System, Sion Surgical Instrument |
| Horizon Therapeutics Plc | $133.56 | 2021-2022 | |
| Eyepoint US, INC. | $130.70 | 2019 | |
| Sandoz INC. | $99.24 | 2024 | Cimerli |
| Coherus Oncology, INC. | $84.86 | 2022-2023 | |
| Ivantis, INC | $67.73 | 2021 | |
| Thea Pharma INC. | $67.10 | 2022-2023 | Iyuzeh |
| Akorn Operating Company LLC | $58.38 | 2021 | |
| Alimera Sciences, INC. | $44.89 | 2023-2024 | Iluvien, Yutiq |
| Regeneron Healthcare Solutions, INC. | $43.89 | 2020-2024 | Eylea |
| Biotissue Holdings INC. | $43.59 | 2021-2024 | |
| The Cameron-Ehlen Group, INC. | $20.97 | 2021 | |
| Eyevance Pharmaceuticals LLC | $20.07 | 2022 | |
| Johnson & Johnson Surgical Vision, INC. | $17.45 | 2025 | Tecnis Simplicity |
| Alcon Research LLC | $17.28 | 2019 | |
| Ocular Therapeutix, INC. | $15.99 | 2021 | |
| Rxsight INC | $13.69 | 2022 | |
| Shire North American Group INC | $12.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Wiles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.